Retrospective Study of Claims-Based Outcomes in Epilepsy: Trokendi XR(R) (extended-release topiramate) vs. Immediate-Release Topiramate
Abstract number :
2.202
Submission category :
7. Antiepileptic Drugs / 7C. Cohort Studies
Year :
2016
Submission ID :
195134
Source :
www.aesnet.org
Presentation date :
12/4/2016 12:00:00 AM
Published date :
Nov 21, 2016, 18:00 PM
Authors :
Welton O'Neal, Supernus Pharmaceuticals, Inc.; Elizabeth E. Hur, Supernus Pharmaceuticals, Inc.; Tesfaye Liranso, Supernus Pharmaceuticals, Inc.; Haechung Chung, Healthcore, Inc.; Tao Gu, Healthcore, Inc.; and Ralph M. Turner, Healthcore, Inc.
Methods: Data source: Medical and pharmacy administrative claims data from HealthCore Integrated Research Database. Intake period [index pharmacy claim for Trokendi XR or TPM-IR]: August 1, 2013 to October 31, 2014. Pre- and post-index period: August 1, 2012 to April 30, 2015. Other inclusion criteria: ?-6 yrs of age at index date; continuous health plan enrollment: ?-12 months pre-index and ?-6 months post-index; ICD-9 diagnostic code for seizures (780.39) or epileptic seizures (345.x). Analyses also examined outcomes in subset with ?-6 months continuous post-index pharmacy fills for study drug ( < 45 day gap in medication possession), including post- vs. pre-index change for claims for potential medication-related complications as proxy for adverse event occurrence. Results: Of 94,141 patients who received Trokendi XR or TPM-IR during intake period, 99 and 1,364 met inclusion criteria and were treated with Trokendi XR and TPM-IR, respectively. Median age was 39 years (14% were children/adolescents); 73% were female. Probability of continuing TPM therapy (survival analysis) was significantly (p=0.005) higher with Trokendi XR vs. TPM-IR; median estimated treatment duration: Trokendi XR, 9.7 months; TPM-IR, 7.5 months. Among all patients, adherence [medication possession ratio (MPR) ?-80%) was significantly (p < 0.001) higher in Trokendi XR cohort (44%) vs. TPM-IR cohort (28%). Medication fill strength was consistent with recommended dose frequency: QD Trokendi XR; BID TPM-IR). Among patients with ?-6 months continuous treatment (Trokendi XR, n=53; TPM-IR, n=568), adherence trended toward significantly higher rates with Trokendi XR (77% vs. 65%, p=0.06). Profile of treatment-emergent complication was not significantly different across cohorts. Conclusions: In this claims-based study, Trokendi XR was associated with significantly greater adherence and persistence with treatment vs. TPM- IR. Analyses of larger datasets are needed to confirm these findings. Funding: Study funded by Supernus Pharmaceuticals, Inc.
Antiepileptic Drugs